HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a single center, non-randomized, open, multi-cohort clinical, exploratory Phase II
study, to evaluate the efficacy and safety of HAIC combined with TQB2450 and anlotinib as
adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after
resection.